LA JOLLA, Calif., Feb. 23 I3 Corporation announced today that the Company will be presenting on its lead product, the Q-FLO(TM) closed system, as a superior alternative to conventional closed systems for medication transport and delivery, at the In3 West Conference on March 4-5, 2010, at the Venetian Resort in Las Vegas, NV.
The Q-FLO(TM) is I3's lead product that encompasses a male and female luer lock mechanism for closed system medication transport and delivery. The Q-FLO(TM) offers unique features and benefits for medication delivery, which include: a) a closed, no drop, valved connection system preventing drips and spillage of cytotoxic drugs, b) convenient locking mechanism allowing for a fast and easy mechanism to establish a patent connection; c) Passive 'Fool Proof' Safety System which seals off upon disconnection to help prevent exposure to hazardous compounds; d) first ever Visual Indicator that provides for a clear, color coded, visual confirmation of the status of the connection; e) the lowest internal residual volume of any closed system on the market; f) rotational actuation, which allows for a pumping action within the male luer connector offering the flexibility of creating a negative, positive, or neutral bolus effect, and finally g) safe material composition, which is entirely Latex, DEHP, and Silicon-free, making the Q-FLO(TM) an ideal connector system for the entire spectrum of chemotherapy and nuclear medicine drugs.
"The Q-FLO(TM) represents a significant advance in the state of the art of closed system devices, offering improved safety and convenience for healthcare workers administering cytotoxic drugs to patients around the world," stated Babak Nemati, Ph.D., President & CEO of I3. "We are proud of the accomplishments of our design and development team, and we look forward to the commercial launch of this important product line with our distribution partners later this year."
In the current hospital environment, thousands of pharmacists, nurses, physicians and other caregivers may encounter a serious threat to their own physical and reproductive health, on a daily basis, through inadvertent exposure to cytotoxic drugs, such as chemotherapy, antivirals, antibiotics, hormones, nuclear medicine drugs. The US federal government estimates that 5.5 million healthcare workers continue to be exposed to these substances each year. Advances in closed systems such as the I3 Q-FLO(TM) offer the promise of creating a safe working environment for healthcare providers worldwide.
About I3 Corporation (www.infusioninnovations.net)
I3 is a La Jolla, California, based emerging medical device company focused on the design and development of innovative products for improved safety of the hospital environment. Founded in 2006, I3 has a strong proprietary portfolio of products ranging from needle-less injection site connectors, to safety syringes, and bio-diagnostic sampling devices. The fundamental driving philosophy behind our products is bringing key engineering innovation to improve safety, ease of use, and functionality of established hospital based products.
For more information, please contact us at email@example.com.
SOURCE I3 Corporation